Skip to main content
Log in

The metabolic fate of the anti-Parkinsonian drug budipine in rats

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The metabolic fate of the anti-Parkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite Mi, and its O-sulphate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide and a secondary metabolite derived from M1 via hydroxylation of a methyl of thetert-butyl group, were isolated and identified in rat urine. The presence of a metabolite M1-glucuronic acid conjugate, was also established through different enzymatic treatments of the rat urine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Iizuka J., Fischer R. (1986): Beeinflussung des Parkinson-tremors durch Budipin. Nervenarzt, 37, 184–186.

    Google Scholar 

  2. Xinde Wang (1985): Observation on the therapeutic effect of budipine in Parkinson’s disease. In: Gerstenbrand F., Poewe W., Stern G. Eds. Clinical Experiences with Budipine. Berlin, Heidelberg, New York, Springer, pp. 158–162.

    Google Scholar 

  3. Jellinger K., Bliesath H. (1987): Adjuvant treatment of Parkinson’s disease with budipine: a double-blind trial versus placebo. J. Neurol. 234, 280–282.

    Article  CAS  PubMed  Google Scholar 

  4. Offermeier J., Van Rooyen J.M. (1985): The pharmacodynamics of budipine on central neurotransmitter systems. In: Gerstenbrand F., Poewe W., Stern G. Eds. Clinical Experiences with Budipine. Berlin Heidelberg, New York, Springer, pp. 93–106.

    Google Scholar 

  5. Zech K., Sturm E., Ludwig G. (1985): Pharmacokinetics and metabolism of budipine in animals and humans. In: Gerstenbrand F., Poewe W., Stern G. Eds. Clinical Experiences with Budipine. Berlin Heidelberg, New York, Springer, pp. 113–121.

    Google Scholar 

  6. Schaefer H., Hackmack G., Eistetter K., Kruger V., Menge H.G., Klose J. (1984): Synthese, physicalisch-chemische eigenschaften und orientirende pharmacologische Untersuchungen von budipin und verwandten 4,4-diphenylpiperidinen. Arzneimittelforsch., 34, 233–240.

    CAS  PubMed  Google Scholar 

  7. Becker H.G.O., Fanghaenel E. (1964): Preparation of Mannich bases with reversibly blocked nitrogen atom. J. Prep. Chem., 26, 58–66.

    Article  CAS  Google Scholar 

  8. Caputo O., Grosa G., Balliano G., Rocco F., Biglino G. (1988): In vitro metabolism of 2-(5-ethylpyridin-2-yl)benzimidazole. Eur. Drug Metab. Pharmacokinet., 13, 47–51.

    Article  CAS  Google Scholar 

  9. Kamm J.J., Szuna A., Kuntzman R. (1972): Studies on unusual N-dealkylation reaction. I. In vivo and in vitro N-dealkylation of N-tert-butylchlorcyclizine to norchlorcyclizine by the rat. Pharmacol. Exp. Ther., 182, 507–514.

    CAS  Google Scholar 

  10. Leitch R.E. (1971): Precise quantitative analysis with stable high-speed liquid-liquid chromatography column. J. Chromatogr., 9, 531–535.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by M. U. R. S. T.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caputo, O., Grosa, G., Ceruti, M. et al. The metabolic fate of the anti-Parkinsonian drug budipine in rats. European Journal of Drug Metabolism and Pharmacokinetics 16, 113–118 (1991). https://doi.org/10.1007/BF03189947

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189947

Keywords

Navigation